The company reported Q1 2026 revenue of $5.3 million, with $2.5 million from recurring sources and $2.9 million from capital equipment sales.
Profound Medical Corp. projected approximately $25 million in revenue for 2026 during its Q1 2026 earnings call. The company reported $5.3 million in revenue for the quarter, split between $2.5 million from recurring revenue and $2.9 million from a one-time capital equipment sale.
Gross margin performance for Q1 2026 was noted, though specific figures were not disclosed. The company anticipates FDA clearance for integration with Siemens Free by year-end, which could expand its market reach.
No immediate market reaction was detailed in the source.